{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:54:22Z","timestamp":1791564862944,"version":"4.3.4"},"reference-count":120,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC-114-2811-E-038-004"],"award-info":[{"award-number":["NSTC-114-2811-E-038-004"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC112-2221-E-038-002-MY3"],"award-info":[{"award-number":["NSTC112-2221-E-038-002-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC114-2628-E-038-001-MY3"],"award-info":[{"award-number":["NSTC114-2628-E-038-001-MY3"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejphar.2026.179277","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:54:47Z","timestamp":1787727287000},"page":"179277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Thymosin \u03b1-1 in cancer therapy: Immunomodulatory mechanisms, clinical applications, and translational perspectives"],"prefix":"10.1016","volume":"1034","author":[{"given":"Sih-Chi","family":"Chuang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Chia","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lekshmi","family":"Rethi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Wei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoa Duc","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9487-2240","authenticated-orcid":false,"given":"Van Khiet","family":"Pham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-7807-8940","authenticated-orcid":false,"given":"Anh Thuy","family":"Vo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hieu Trung","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Yi","family":"Tzou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1593-4573","authenticated-orcid":false,"given":"Andrew E.-Y.","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2026.179277_bib1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1749-6632.1979.tb47100.x","article-title":"T-lymphocyte maturation: cell surface markers and immune function induced by t-lymphocyte cell-free products and thymosin polypeptides","volume":"332","author":"Ahmed","year":"1979","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2026.179277_bib2","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.3748\/wjg.v25.i28.3704","article-title":"Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma","volume":"25","author":"Akateh","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.ejphar.2026.179277_bib3","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/hep.24710","article-title":"Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008","volume":"55","author":"Altekruse","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2026.179277_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2217\/imt.11.159","article-title":"Immunotherapy against invasive mold infections","volume":"4","author":"Antachopoulos","year":"2012","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ejphar.2026.179277_bib5","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.clinbiochem.2005.01.013","article-title":"Thymosin alpha 1 attenuates lipid peroxidation and improves fructose-induced steatohepatitis in rats","volume":"38","author":"Armutcu","year":"2005","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.ejphar.2026.179277_bib6","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1210\/endo-86-3-600","article-title":"Reduction in the incidence of wasting disease in neonatally thymectomized CBA\/W mice by the injection of thymosin","volume":"86","author":"Asanuma","year":"1970","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2026.179277_bib7","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3109\/07357909409021409","article-title":"Thymosin alpha-1 as adjunct for conventional therapy of malignant tumors: a review","volume":"12","author":"Bepler","year":"1994","journal-title":"Cancer Invest."},{"key":"10.1016\/j.ejphar.2026.179277_bib8","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.2217\/fon-2020-0754","article-title":"The right immune-modulation at the right time: thymosin \u03b11 for prevention of severe COVID-19 in cancer patients","volume":"17","author":"Bersanelli","year":"2021","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejphar.2026.179277_bib9","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1089\/ten.1999.5.499","article-title":"Age-and disease-related decline in immune function: an opportunity for \u201cthymus-boosting\u201d therapies","volume":"5","author":"Berthiaume","year":"1999","journal-title":"Tissue Eng."},{"key":"10.1016\/j.ejphar.2026.179277_bib10","doi-asserted-by":"crossref","first-page":"7255","DOI":"10.2147\/OTT.S177943","article-title":"Thymosin \u03b11 suppresses migration and invasion of PD-L1 high-expressing non-small-cell lung cancer cells via inhibition of STAT3-MMP2 signaling","volume":"11","author":"Bo","year":"2018","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejphar.2026.179277_bib11","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1093\/intimm\/dxm097","article-title":"Thymosin \u03b11 activates the TLR9\/MyD88\/IRF7-dependent murine cytomegalovirus sensing for induction of anti-viral responses in vivo","volume":"19","author":"Bozza","year":"2007","journal-title":"Int. Immunol."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2026.179277_bib12","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1517\/14712598.2015.1033393","article-title":"Historical review of thymosin \u03b1 1 in infectious diseases","volume":"15","author":"Camerini","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ejphar.2026.179277_bib13","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.vaccine.2011.12.014","article-title":"Thymosin-alpha 1 (Zadaxin) enhances the immunogenicity of an adjuvated pandemic H1N1v influenza vaccine (Focetria) in hemodialyzed patients: a pilot study","volume":"30","author":"Carraro","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.ejphar.2026.179277_bib14","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/j.cell.2025.02.002","article-title":"Bacterial immunotherapy leveraging IL-10R hysteresis for both phagocytosis evasion and tumor immunity revitalization","volume":"188","author":"Chang","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.ejphar.2026.179277_bib15","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1016\/j.immuni.2023.07.015","article-title":"CTLA-4 blockade induces a microglia-Th1 cell partnership that stimulates microglia phagocytosis and anti-tumor function in glioblastoma","volume":"56","author":"Chen","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.ejphar.2026.179277_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107829","article-title":"Combination of gemcitabine and thymosin alpha 1 exhibit a better anti-tumor effect on nasal natural killer\/T-cell lymphoma","volume":"98","author":"Chen","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejphar.2026.179277_bib17","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/curroncol33030173","article-title":"Comparative efficacy and safety of first-line immune checkpoint inhibitors plus chemotherapy with or without Bevacizumab in advanced non-squamous non-small cell lung carcinoma","volume":"33","author":"Chen","year":"2026","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejphar.2026.179277_bib18","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1002\/hep.510270527","article-title":"Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trial","volume":"27","author":"Chien","year":"1998","journal-title":"Hepatology"},{"key":"10.1016\/j.ejphar.2026.179277_bib20","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3389\/fonc.2019.00873","article-title":"A reappraisal of Thymosin Alpha1 in cancer therapy","volume":"9","author":"Costantini","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejphar.2026.179277_bib21","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1080\/14712598.2018.1494717","article-title":"Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy","volume":"18","author":"Danielli","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ejphar.2026.179277_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5501\/wjv.v9.i5.67","article-title":"Thymosin alpha 1: a comprehensive review of the literature","volume":"9","author":"Dominari","year":"2020","journal-title":"World J. Virol."},{"key":"10.1016\/j.ejphar.2026.179277_bib26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/0192-0561(85)90065-7","article-title":"Effect of thymosin alpha one on specific antibody response and susceptibility to infection in young and aged mice","volume":"7","author":"Ershler","year":"1985","journal-title":"Int. J. Immunopharm."},{"key":"10.1016\/j.ejphar.2026.179277_bib27","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF00916574","article-title":"Influenza and aging: age-related changes and the effects of thymosin on the antibody response to influenza vaccine","volume":"4","author":"Ershler","year":"1984","journal-title":"J. Clin. Immunol."},{"key":"10.1016\/j.ejphar.2026.179277_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.111103","article-title":"Immune modulation via dendritic cells by the effect of Thymosin-alpha-1 on immune synapse in HCMV infection","volume":"125","author":"Espinar-Buitrago","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejphar.2026.179277_bib29","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1111\/j.1365-2036.2006.02923.x","article-title":"Meta\u2010analysis: the adjuvant role of thymopentin on immunological response to hepatitis B virus vaccine in end\u2010stage renal disease","volume":"23","author":"Fabrizi","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2026.179277_bib30","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/BF00205574","article-title":"Modulation of natural killer activity by thymosin alpha 1 and interferon","volume":"20","author":"Favalli","year":"1985","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejphar.2026.179277_bib31","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1097\/TA.0000000000000909","article-title":"Ulinastatin and\/or thymosin \u03b11 for severe sepsis: a systematic review and meta-analysis","volume":"80","author":"Feng","year":"2016","journal-title":"J. Trauma Acute Care Surg."},{"key":"10.1016\/j.ejphar.2026.179277_bib32","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1196\/annals.1415.039","article-title":"Thymosin \u03b11: a historical overview","volume":"1112","author":"Garaci","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2026.179277_bib33","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1196\/annals.1415.044","article-title":"Thymosin alpha 1: from bench to bedside","volume":"1112","author":"Garaci","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2026.179277_bib34","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1016\/0959-8049(95)00477-7","article-title":"Sequential chemoimmunotherapy for advanced non-small cell lung cancer using cisplatin, etoposide, thymosin-alpha 1 and interferon-alpha 2a","volume":"31a","author":"Garaci","year":"1995","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejphar.2026.179277_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2024.1388959","article-title":"Phenotypic drug discovery: a case for thymosin alpha-1","volume":"11","author":"Garaci","year":"2024","journal-title":"Front. Med."},{"key":"10.1016\/j.ejphar.2026.179277_bib36","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1517\/14712598.2015.1017466","article-title":"Historical review on thymosin \u03b11 in oncology: preclinical and clinical experiences","volume":"15","author":"Garaci","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ejphar.2026.179277_bib37","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/S0192-0561(00)00075-8","article-title":"Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application","volume":"22","author":"Garaci","year":"2000","journal-title":"Int. J. Immunopharm."},{"key":"10.1016\/j.ejphar.2026.179277_bib38","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/S1567-5769(03)00053-5","article-title":"Thymosin alpha(1) in combination with cytokines and chemotherapy for the treatment of cancer","volume":"3","author":"Garaci","year":"2003","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejphar.2026.179277_bib39","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1352458517695892","article-title":"Thymosin-\u03b11 expands deficient IL-10-producing regulatory B cell subsets in relapsing\u2013remitting multiple sclerosis patients","volume":"24","author":"Giacomini","year":"2018","journal-title":"Multipl. Scler. J."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2026.179277_bib40","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1517\/14712598.2015.1019460","article-title":"Dual effect of Thymosin \u03b1 1 on human monocyte-derived dendritic cell in vitro stimulated with viral and bacterial toll-like receptor agonists","volume":"15","author":"Giacomini","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ejphar.2026.179277_bib41","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1002\/1521-4141(200003)30:3<778::AID-IMMU778>3.0.CO;2-I","article-title":"Thymosin-\u03b11 regulates MHC class I expression in FRTL-5 cells at transcriptional level","volume":"30","author":"Giuliani","year":"2000","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ejphar.2026.179277_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1196\/annals.1415.045","article-title":"History of the discovery of the thymosins","volume":"1112","author":"Goldstein","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2026.179277_bib43","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4049\/jimmunol.104.2.359","article-title":"Influence of thymosin on cell-mediated and humoral immune responses in normal and in immunologically deficient mice","volume":"104","author":"Goldstein","year":"1970","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2026.179277_bib45","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1517\/14712590902911412","article-title":"From lab to bedside: emerging clinical applications of thymosin \u03b11","volume":"9","author":"Goldstein","year":"2009","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ejphar.2026.179277_bib46","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1073\/pnas.74.2.725","article-title":"Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide","volume":"74","author":"Goldstein","year":"1977","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejphar.2026.179277_bib47","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1073\/pnas.56.3.1010","article-title":"Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin)","volume":"56","author":"Goldstein","year":"1966","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejphar.2026.179277_bib48","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.179277_bib49","first-page":"1","article-title":"Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy","volume":"10","author":"Graff","year":"2015","journal-title":"Core Evid."},{"key":"10.1016\/j.ejphar.2026.179277_bib50","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s10495-015-1138-9","article-title":"Thymosin alpha 1 suppresses proliferation and induces apoptosis in breast cancer cells through PTEN-mediated inhibition of PI3K\/Akt\/mTOR signaling pathway","volume":"20","author":"Guo","year":"2015","journal-title":"Apoptosis"},{"key":"10.1016\/j.ejphar.2026.179277_bib51","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejphar.2026.179277_bib52","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1073\/pnas.81.5.1391","article-title":"Distribution of prothymosin alpha in rat tissues","volume":"81","author":"Haritos","year":"1984","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejphar.2026.179277_bib53","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1749-6632.1975.tb29063.x","article-title":"Purification and properties of bovine thymosin","volume":"249","author":"Hooper","year":"1975","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2026.179277_bib55","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2026.179277_bib56","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/s41573-022-00493-5","article-title":"Adaptive immune resistance at the tumour site: mechanisms and therapeutic opportunities","volume":"21","author":"Kim","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2026.179277_bib57","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/bs.vh.2016.04.003","article-title":"Immune modulation with thymosin alpha 1 treatment","volume":"102","author":"King","year":"2016","journal-title":"Vitam. Horm."},{"key":"10.1016\/j.ejphar.2026.179277_bib59","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1517\/14712598.2015.1008446","article-title":"Evaluation of thymosin \u03b1 1 in nonclinical models of the immune-suppressing indications melanoma and sepsis","volume":"15","author":"King","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ejphar.2026.179277_bib60","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0192-0561(98)00060-5","article-title":"Thymosin-\u03b11 stimulates maturation of CD34+ stem cells into CD3+4+ cells in an in vitro thymic epithelia organ coculture model","volume":"21","author":"Knutsen","year":"1999","journal-title":"Int. J. Immunopharm."},{"key":"10.1016\/j.ejphar.2026.179277_bib61","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/nature18935","article-title":"CD47-blocking antibodies restore phagocytosis and prevent atherosclerosis","volume":"536","author":"Kojima","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.179277_bib62","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1038\/2191391a0","article-title":"Influence of thymosin on immunological competence of lymphoid cells from thymectomized mice","volume":"219","author":"Law","year":"1968","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2026.179277_bib63","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ijid.2014.12.032","article-title":"Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis","volume":"33","author":"Li","year":"2015","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ejphar.2026.179277_bib64","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.peptides.2010.07.026","article-title":"Thymosin alpha 1: biological activities, applications and genetic engineering production","volume":"31","author":"Li","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.ejphar.2026.179277_bib66","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijrobp.2022.07.009","article-title":"Efficacy of thymosin \u03b11 in management of radiation pneumonitis in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy: a phase 2 clinical trial (GASTO-1043)","volume":"114","author":"Liu","year":"2022","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.ejphar.2026.179277_bib67","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1186\/s12879-016-1823-5","article-title":"The efficacy of thymosin \u03b11 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials","volume":"16","author":"Liu","year":"2016","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.ejphar.2026.179277_bib68","article-title":"Thymosin \u03b11 reverses oncolytic adenovirus-induced M2 polarization of macrophages to improve antitumor immunity and therapeutic efficacy","volume":"5","author":"Liu","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ejphar.2026.179277_bib69","article-title":"Mechanism and clinical application of thymosin in the treatment of lung cancer","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.179277_bib71","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1093\/cid\/ciaa630","article-title":"Thymosin alpha 1 reduces the mortality of severe coronavirus disease 2019 by restoration of Lymphocytopenia and reversion of exhausted T cells","volume":"71","author":"Liu","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejphar.2026.179277_bib72","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S0021-9258(17)37901-2","article-title":"The chemistry and biology of thymosin","volume":"254","author":"Low","year":"1979","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2026.179277_bib73","article-title":"Immunotherapy: reshape the tumor immune microenvironment","volume":"13","author":"Lv","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.179277_bib74","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109952","article-title":"Thymosin alpha 1 \u2013 reimagine its broader applications in the immuno-oncology era","volume":"117","author":"Mao","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejphar.2026.179277_bib75","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2217\/fmb-2016-0125","article-title":"Thymosin alpha 1 and HIV-1: recent advances and future perspectives","volume":"12","author":"Matteucci","year":"2017","journal-title":"Future Microbiol."},{"issue":"128","key":"10.1016\/j.ejphar.2026.179277_bib76","doi-asserted-by":"crossref","first-page":"368","DOI":"10.4049\/jimmunol.128.1.368","article-title":"Immunochemical studies on thymosin: radioimmunoassay of thymosin alpha 1","author":"McClure","year":"1982","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2026.179277_bib78","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1196\/annals.1415.040","article-title":"Thymosin \u03b11 as a chemopreventive agent in lung and breast cancer","volume":"1112","author":"Moody","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2026.179277_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.105064","article-title":"AI-enhanced synergistic chemo-immunotherapy: from mechanistic insights to clinical translation","volume":"217","author":"Muhammad","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejphar.2026.179277_bib81","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1196\/annals.1415.036","article-title":"Immunopharmacology of thymosin \u03b11 and cytokine synergy","volume":"1112","author":"Naylor","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2026.179277_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109166","article-title":"Thymosin alpha 1 as an adjuvant to hyperthermic intraperitoneal chemotherapy in an experimental model of peritoneal metastases from colonic carcinoma","volume":"111","author":"Nevo","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejphar.2026.179277_bib84","first-page":"111","article-title":"Utility of thymosin alpha-1 (Zadaxin) as a co-adjuvant in influenza vaccines: a review","volume":"52","author":"Panatto","year":"2011","journal-title":"J. Prev. Med. Hyg."},{"key":"10.1016\/j.ejphar.2026.179277_bib85","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1186\/s12876-020-01477-8","article-title":"The clinical efficacy and adverse effects of Entecavir plus Thymosin alpha-1 combination therapy versus Entecavir Monotherapy in HBV-related cirrhosis: a systematic review and meta-analysis","volume":"20","author":"Peng","year":"2020","journal-title":"BMC Gastroenterol."},{"key":"10.1016\/j.ejphar.2026.179277_bib87","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/cei.12833","article-title":"Serum thymosin \u03b1 1 levels in patients with chronic inflammatory autoimmune diseases","volume":"186","author":"Pica","year":"2016","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ejphar.2026.179277_bib89","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/14712598.2018.1474197","article-title":"Serum thymosin alpha 1 levels in normal and pathological conditions","volume":"18","author":"Pica","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ejphar.2026.179277_bib92","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1182\/blood.V68.2.493.493","article-title":"Treatment of hairy cell leukemia with recombinant \u03b1-Interferon","volume":"68","author":"Quesada","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.179277_bib93","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/ijc.2910570516","article-title":"Anti-tumor effect of combined treatment with thymosin alpha 1 and interleukin-2 after 5-fluorouracil in liver metastases from colorectal cancer in rats","volume":"57","author":"Rasi","year":"1994","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2026.179277_bib94","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1097\/00008390-200010020-00012","article-title":"Combined treatment with thymosin-alpha1 and low dose interferon-alpha after dacarbazine in advanced melanoma","volume":"10","author":"Rasi","year":"2000","journal-title":"Melanoma Res."},{"key":"10.1016\/j.ejphar.2026.179277_bib95","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202000662","article-title":"Thymosin \u03b11 protects from CTLA-4 intestinal immunopathology","volume":"3","author":"Renga","year":"2020","journal-title":"Life Sci. Alliance"},{"key":"10.1016\/j.ejphar.2026.179277_bib96","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/jnci\/djac172","article-title":"Breast cancer screening during the COVID-19 pandemic: moving from disparities to health equity","volume":"115","author":"Richman","year":"2023","journal-title":"JNCI: J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejphar.2026.179277_bib97","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejphar.2026.179277_bib98","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1182\/blood-2003-11-4036","article-title":"Thymosin \u03b1 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling","volume":"103","author":"Romani","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.179277_bib100","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1196\/annals.1415.002","article-title":"Thymosin \u03b11: an endogenous regulator of inflammation, immunity, and tolerance","volume":"1112","author":"Romani","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2026.179277_bib102","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1182\/blood-2006-02-004762","article-title":"Thymosin \u03b11 activates dendritic cell tryptophan catabolism and establishes a regulatory environment for balance of inflammation and tolerance","volume":"108","author":"Romani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2026.179277_bib103","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/nm.4305","article-title":"Thymosin \u03b11 represents a potential potent single-molecule-based therapy for cystic fibrosis","volume":"23","author":"Romani","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejphar.2026.179277_bib104","first-page":"1001","article-title":"Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial","volume":"16","author":"Salvati","year":"1996","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejphar.2026.179277_bib105","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.179277_bib106","first-page":"147","article-title":"A randomized trial to evaluate the immunorestorative properties of synthetic thymosin-alpha 1 in patients with lung cancer","volume":"4","author":"Schulof","year":"1985","journal-title":"J. Biol. Response Modif."},{"issue":"Suppl. 1","key":"10.1016\/j.ejphar.2026.179277_bib107","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1517\/14712598.2015.1024221","article-title":"Thymosin \u03b11 modifies podosome architecture and promptly stimulates the expression of podosomal markers in mature macrophages","volume":"15","author":"Serafino","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ejphar.2026.179277_bib108","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000351587","article-title":"Thymosin \u03b11 activates complement receptor-mediated phagocytosis in human monocyte-derived macrophages","volume":"6","author":"Serafino","year":"2014","journal-title":"J. Innate Immun."},{"key":"10.1016\/j.ejphar.2026.179277_bib109","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.4049\/jimmunol.139.7.2338","article-title":"Modulation of human natural killer cell cytotoxic activity, lymphokine production, and interleukin 2 receptor expression by thymic hormones","volume":"139","author":"Serrate","year":"1987","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejphar.2026.179277_bib110","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/vim.1991.4.195","article-title":"Low thymosin alpha-1 concentrations in patients chronically infected with the hepatitis B virus","volume":"4","author":"Sherman","year":"1991","journal-title":"Viral Immunol."},{"key":"10.1016\/j.ejphar.2026.179277_bib111","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/039463200401700106","article-title":"Activation of tumor-associated macrophages by thymosin alpha 1","volume":"17","author":"Shrivastava","year":"2004","journal-title":"Int. J. Immunopathol. Pharmacol."},{"key":"10.1016\/j.ejphar.2026.179277_bib112","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejphar.2026.179277_bib113","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s002620050562","article-title":"Efficacy of repeated cycles of chemo-immunotherapy with Thymosin \u03b11 and interleukin-2 after intraperitoneal 5-fluorouracil delivery","volume":"48","author":"Silecchia","year":"1999","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejphar.2026.179277_bib114","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF02786456","article-title":"Thymopentin and splenopentin as immunomodulators: current status","volume":"17","author":"Singh","year":"1998","journal-title":"Immunol. Res."},{"key":"10.1016\/j.ejphar.2026.179277_bib115","doi-asserted-by":"crossref","first-page":"995","DOI":"10.2147\/OTT.S527785","article-title":"The immunomodulatory activity of thymosin alpha 1 on tumor cell lines and distinct immune cell subsets","volume":"18","author":"Solmonese","year":"2025","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejphar.2026.179277_bib116","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1386-6346(02)00145-6","article-title":"Thymosin-alpha1 increases intrahepatic NKT cells and CTLs in patients with chronic hepatitis B","volume":"24","author":"Sugahara","year":"2002","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.ejphar.2026.179277_bib117","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70496","article-title":"Dynamic evolution of the tumor immune microenvironment in malignant tumors and emerging therapeutic paradigms","volume":"6","author":"Sun","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.ejphar.2026.179277_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111776","article-title":"The complex roles of efferocytosis in cancer development, metastasis, and treatment","volume":"140","author":"Tajbakhsh","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ejphar.2026.179277_bib120","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.thorsurg.2018.12.001","article-title":"The role of the thymus in the immune response","volume":"29","author":"Thapa","year":"2019","journal-title":"Thorac. Surg. Clin."},{"key":"10.1016\/j.ejphar.2026.179277_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1571456","article-title":"Thymosin alpha 1 alleviates inflammation and prevents infection in patients with severe acute pancreatitis through immune regulation: a systematic review and meta-analysis","volume":"16","author":"Tian","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.179277_bib122","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1749-6632.2012.06680.x","article-title":"Thymosin \u03b11 continues to show promise as an enhancer for vaccine response","volume":"1270","author":"Tuthill","year":"2012","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2026.179277_bib123","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1749-6632.2010.05482.x","article-title":"Thymosin alpha 1: past clinical experience and future promise","volume":"1194","author":"Tuthill","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2026.179277_bib124","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1208\/pt010211","article-title":"Quantitative analysis of thymosin \u03b11 in human serum by LC-MS\/MS","volume":"1","author":"Tuthill","year":"2000","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejphar.2026.179277_bib125","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/0162-3109(89)90063-5","article-title":"Thymosins alpha 1 and beta 4 potentiate the antigen-presenting capacity of macrophages","volume":"18","author":"Tzehoval","year":"1989","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.ejphar.2026.179277_bib126","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1158\/1055-9965.EPI-22-0544","article-title":"Impact and recovery from COVID-19\u2013Related disruptions in colorectal cancer screening and care in the US: a scenario analysis","volume":"32","author":"Van den Puttelaar","year":"2023","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ejphar.2026.179277_bib127","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/0192-0561(88)90002-1","article-title":"Improved ELISA to measure thymosin \u03b11: comparison of whole and absorbed antisera","volume":"10","author":"Wada","year":"1988","journal-title":"Int. J. Immunopharm."},{"key":"10.1016\/j.ejphar.2026.179277_bib128","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s12264-017-0162-x","article-title":"Immunopotentiator thymosin Alpha-1 promotes neurogenesis and cognition in the developing mouse via a systemic Th1 bias","volume":"33","author":"Wang","year":"2017","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.ejphar.2026.179277_bib129","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.2147\/CMAR.S542744","article-title":"Thymosin \u03b11 combined with PD-1\/PD-L1 inhibitor plus chemotherapy in platinum-resistant recurrent ovarian cancer : a retrospective analysis","volume":"17","author":"Wang","year":"2025","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.ejphar.2026.179277_bib130","article-title":"Advances in targeting tumor microenvironment for immunotherapy","volume":"15","author":"Wang","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejphar.2026.179277_bib132","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.109744","article-title":"Thymosin \u03b1-1 in cancer therapy: immunoregulation and potential applications","volume":"117","author":"Wei","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ejphar.2026.179277_bib131","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1158\/0008-5472.CAN-21-4260","article-title":"Thymosin \u03b1-1 reverses M2 polarization of tumor-associated macrophages during efferocytosis","volume":"82","author":"Wei","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2026.179277_bib134","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.e21524","article-title":"Therapeutic advantages of thymosin \u03b11 combined with toripalimab for elderly patients with advanced melanoma: preliminary results from a phase II study","volume":"43","author":"Wen","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2026.179277_bib135","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/cc11932","article-title":"The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial","volume":"17","author":"Wu","year":"2013","journal-title":"Crit. Care"},{"key":"10.1016\/j.ejphar.2026.179277_bib136","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.2147\/CMAR.S555975","article-title":"Thymosin \u03b11 elevates lymphocyte counts and improves immunoradiotherapy outcomes in patients with advanced cancer","volume":"17","author":"Xu","year":"2025","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.ejphar.2026.179277_bib139","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.imlet.2007.04.007","article-title":"Thymosin-\u03b11 modulates dendritic cell differentiation and functional maturation from human peripheral blood CD14+ monocytes","volume":"110","author":"Yao","year":"2007","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.ejphar.2026.179277_bib140","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1111\/j.1440-1746.2006.04699.x","article-title":"Thymosin alpha 1 improves severe acute pancreatitis in rats via regulation of peripheral T cell number and cytokine serum level","volume":"22","author":"Yao","year":"2007","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.ejphar.2026.179277_bib141","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.21037\/tlcr-2025-190","article-title":"A preliminary analysis of integrating thymosin \u03b11 into concurrent chemoradiotherapy and consolidative immunotherapy in unresectable locally advanced non-small cell lung cancer","volume":"14","author":"Zhang","year":"2025","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.ejphar.2026.179277_bib142","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.gendis.2020.02.002","article-title":"Adjuvant therapies after curative treatments for hepatocellular carcinoma: current status and prospects","volume":"7","author":"Zhu","year":"2020","journal-title":"Genes Dis."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926007594?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299926007594?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:18:30Z","timestamp":1791562710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299926007594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":120,"alternative-id":["S0014299926007594"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179277","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thymosin \u03b1-1 in cancer therapy: Immunomodulatory mechanisms, clinical applications, and translational perspectives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2026.179277","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"179277"}}